Bovine double-interferon gene, recombinant pichia pastoris engineering bacterium, and preparation method and application of recombinant pichia pastoris engineering bacterium

By removing signal peptides and knocking out the Prb1 gene in the Pichia cerevisia expression system, the problems of incomplete function and high purification difficulty of recombinant bovine interferon in the prokaryotic system are solved, efficient expression and secretion are achieved, production costs are reduced, and production costs are met. Market demand.

CN119061038APending Publication Date: 2024-12-03LIAOCHENG UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411335077.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the prior art, recombinant bovine interferon is mainly obtained through a prokaryotic expression system, resulting in proteins present in bacteria and inclusion bodies, incomplete functions, and the subsequent purification process is complex and costly, making it difficult to meet market demand.

Method used

By removing signal peptides, adding Pichia signal peptide α-mating factor, inserting translation enhancer, and knocking out the Prb1 gene, it promotes the secretion and modification of recombinant bovine interferon, improves the expression efficiency of proteins and Functional.

Benefits of technology

The efficient expression and secretion of recombinant bovine interferon was achieved, and the problem of proteins present in bacteria and inclusion bodies in prokaryotic expression was solved, which improved the functional and purification efficiency of proteins, and reduced production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061038A_ABST
    Figure CN119061038A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of bovine interferon genes, in particular to a bovine double-interferon gene, recombinant pichia pastoris engineering bacteria as well as a preparation method and application of the recombinant pichia pastoris engineering bacteria. The invention provides a bovine double-interferon gene in an optional embodiment, and the nucleotide sequence of the bovine double-interferon gene is shown as SEQ ID NO. 1. After signal peptides of BoIFN-alpha and BoIFN-lambda are deleted, a pichia pastoris signal peptide alpha-mating factor is added, a section of translation enhancer is inserted, PDI protein is overexpressed in pichia pastoris, Prb1 gene is knocked out, translation and modification of protein are promoted, recombinant bovine interferon can be secreted into supernate, and the recombinant bovine interferon can be secreted into the supernate. The problem that protein mainly exists in bacteria and inclusion bodies in prokaryotic expression is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of bovine interferon genes, and in particular to a bovine double interferon gene, a recombinant Pichia pastoris engineering bacterium, and a preparation method and application thereof. Background Art

[0002] Interferon (IFN) is an important immune regulatory factor in the body and plays an important role in the prevention, control and treatment of diseases. Studies have shown that recombinant BoIFN-α has a preventive effect on bovine respiratory diseases. The application of BoIFN-α to growing calves can reduce the incidence and mortality of respiratory diseases. Bovine interferon λ (BoIFN-λ) belongs to type III interferon and also has antiviral, anti-tumor and immunomodulatory effects. Because it only exerts biological activity in specific tissues and cells such as the respiratory tract, digestive tract, skin mucosa, liver and lung tissues, it has a good protective effect against respiratory and digestive tract infectious diseases such as foot-and-mouth disease and bovine viral diarrhea.

[0003] After long-term practice and verification, interferon has been proven to be an efficient and safe treatment method that can effectively prevent and treat a variety of viral diseases. At present, China has approved new veterinary drugs, veterinary biological products or clinical trials for multiple interferon products, such as recombinant canine α interferon, recombinant cat ω interferon, recombinant chicken α interferon, recombinant porcine α interferon, etc., but there is no approval for bovine interferon products. Some studies have linked expression elements in series on prokaryotic expression vectors to increase protein expression, but the target protein still mainly exists in cells or inclusion bodies, and may cause changes in the tertiary structure of the target protein, thereby affecting the relevant functions of the target protein. There are also studies that connect the bovine interferon gene to a low-temperature expression vector to improve protein soluble expression, but the total protein expression is also reduced. In addition, in order to obtain the target protein in Escherichia coli, it is necessary to collect and lyse the bacteria, collect the supernatant, remove the bacterial endotoxin, purify and renature the target protein. These operation steps are more, the temperature and reagents are strictly controlled, and the target protein loss is large. When used in the production of livestock and poultry biological products in the later stage, the product preparation process is difficult and costly, which is not conducive to market promotion and sales.

[0004] The eukaryotic expression system can be used to obtain recombinant proteins that are more similar to the natural conformation. Currently, the most commonly used eukaryotic expression systems are yeast expression systems, mammalian expression systems, and insect cell expression systems. They have advantages such as post-transcriptional processing systems, post-translational modification systems, and the ability to truly achieve exocrine secretion of heterologous proteins. They overcome the defects of prokaryotic expression systems such as the lack of post-transcriptional shearing and processing systems and the inability to perform effective glycosylation, phosphorylation, and methylation. The Pichia pastoris expression system has become one of the most important eukaryotic systems for protein production due to its advantages such as high protein yield, high activity, good stability and safety. It has been fully developed and utilized in recent years. Compared with other eukaryotic expression systems, the Pichia pastoris expression products are more soluble, easy to purify, and have a high recovery rate, so they are more suitable for the production of protein drugs.

[0005] There is no product on the market that contains both BoIFN-α and BoIFN-λ proteins. Currently, recombinant bovine interferon is mostly obtained by prokaryotic expression system (Escherichia coli). Although Escherichia coli has the advantages of rapid growth and simple culture conditions, the target protein expressed by Escherichia coli has poor folding and cannot be post-translationally modified. As a result, the recombinant bovine interferon obtained by this method is different from the natural bovine interferon in conformation, which causes its incomplete function. In addition, the secretory protein of Escherichia coli is prone to form inclusion bodies, which increases the difficulty of subsequent purification. In the later stage, it is necessary to lyse bacteria, remove bacterial endotoxins, purify and renature the target protein. There are many operating steps and strict control conditions, which makes the product production process difficult and costly, which is not conducive to market promotion and sales, and cannot meet the needs of bovine interferon product production. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a bovine double interferon gene, a recombinant Pichia pastoris engineered bacterium, and a preparation method and application thereof. The present invention deletes the signal peptides of BoIFN-α and BoIFN-λ, adds the Pichia pastoris signal peptide α-mating factor, inserts a translation enhancer, overexpresses the PDI protein in Pichia pastoris, knocks out the Prb1 gene, promotes the translation and modification of the protein, and enables the recombinant bovine interferon to be secreted into the supernatant, thereby solving the problem that the protein mainly exists in bacteria and inclusion bodies in prokaryotic expression.

[0007] To this end, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a bovine double interferon gene in an optional embodiment, and the nucleotide sequence of the bovine double interferon gene is shown in SEQ ID NO.1.

[0009] In a second aspect, the present invention provides a method for preparing the above-mentioned bovine double interferon gene in an optional embodiment, comprising the following steps:

[0010] S1: RNA was extracted from bovine spleen lymphocytes stimulated with ConA and reverse transcribed, and PCR amplification was performed using amplification primers using RNA as a template to recover and sequence the bovine interferon α and bovine interferon λ genes to obtain BoIFN-α and BoIFN-λ sequences;

[0011] S2: After removing the signal peptide sequence from the BoIFN-α and BoIFN-λ sequences, the two gene sequences were connected using a flexible linker to obtain the BoIFN-α-λ sequence;

[0012] S3: After the Pichia pastoris signal peptide α-mating factor is connected to the N-terminus of the enhancer through the self-cleaving 2A peptide, the C-terminus of the enhancer is connected to the BoIFN-α-λ sequence through the self-cleaving 2A peptide to obtain the enhancer-BoIFN-α-λ sequence;

[0013] S4: After replacing the rare codons in the enhancer-BoIFN-α-λ sequence with the Pichia pastoris dominant codons, eliminating the AT-rich region and adjusting the G+C content in the sequence to be consistent with the G+C content in Pichia pastoris, the bovine bi-interferon gene is obtained.

[0014] In a third aspect, the present invention provides, in an optional embodiment, a recombinant expression vector containing the bovine dual interferon gene.

[0015] In a fourth aspect, the present invention provides, in an optional embodiment, a host cell containing the above-mentioned recombinant expression vector.

[0016] In a fifth aspect, the present invention provides, in an optional embodiment, a recombinant Pichia pastoris engineered bacterium that expresses the above-mentioned bovine double interferon gene.

[0017] Preferably, the biological preservation number of the recombinant Pichia pastoris engineered bacteria is: CCTCC NO: M20241194, it was deposited in the China Center for Type Culture Collection on June 11, 2024, the preservation address is Wuhan University, Wuhan, China, the classification name is Pichia pastoris LCUBCI3-31, and the preservation status is alive.

[0018] In a sixth aspect, the present invention provides, in an optional embodiment, a method for preparing the above-mentioned recombinant Pichia pastoris engineered bacteria, comprising the following steps:

[0019] (1) connecting the above-mentioned bovine dual interferon gene to the pPIC9K vector to obtain the pPIC9K-enhancer-BoIFN-α-λ recombinant vector;

[0020] (2) After linearizing the pPIC9K-enhancer-BoIFN-α-λ recombinant vector, transforming it into competent cells GS115, culturing it, identifying, inducing and screening it, and obtaining a GS115-enhancer-BoIFN-α-λ recombinant strain;

[0021] (3) After codon optimization, the molecular chaperone PDI was cloned into the pPICZαA vector to obtain the pPICZαA-PDI recombinant vector;

[0022] (4) After linearization, the pPICZαA-PDI recombinant vector was transformed into the competent cell GS115-enhancer-BoIFN-α-λ and cultured to obtain the GS115-enhancer-BoIFN-α-λ-PDI recombinant strain;

[0023] (5) After knocking out the Prb1 gene in the GS115-enhancer-BoIFN-α-λ-PDI recombinant strain, identification, induction and screening were performed to obtain the recombinant Pichia pastoris engineered strain GS115-enhancer-BoIFN-α-λ-PDI-ΔPrb1.

[0024] Preferably, in step (2) and step (5), the induction method is:

[0025] The identified strains were inoculated into YPD medium at 1% inoculation volume, and cultured at 30°C and 250 r / min for 16-18 h. Then, the YPD culture was inoculated into BMGY medium at 10% inoculation volume, and cultured at 30°C and 250 r / min until OD 600 When the OD reaches 2.0-6.0, the bacterial solution is centrifuged and the cell pellet is resuspended in BMMY medium to an OD of 600 was 1.0, and finally induced culture was carried out at 28°C and a stirring speed of 250 r / min. 100% methanol was added every 24 hours to a final concentration of 0.5%, and culture was continued for 96 hours.

[0026] In a seventh aspect, the present invention provides, in an optional embodiment, a use of the above-mentioned recombinant Pichia pastoris engineered bacteria in combating bovine viral diseases.

[0027] Preferably, the bovine viral diseases include foot-and-mouth disease and bovine viral diarrhea.

[0028] The nucleotide sequence of SEQ ID NO.1 is as follows:

[0029]

[0030] Compared with the prior art, the present invention has one of the following beneficial effects:

[0031] 1. The present invention deletes the signal peptides of BoIFN-α and BoIFN-λ, adds the Pichia pastoris signal peptide α-mating factor, inserts a translation enhancer, overexpresses the PDI protein in Pichia pastoris, knocks out the Prb1 gene, promotes the translation and modification of the protein, enables the recombinant bovine interferon to be secreted into the supernatant, improves the expression efficiency of BoIFN-α and BoIFN-λ, and solves the problem that the protein mainly exists in bacteria and inclusion bodies in prokaryotic expression.

[0032] 2. Under the premise of ensuring that the amino acid sequence remains unchanged, the present invention optimizes the gene sequence by yeast codons, eliminates AT-rich regions, adjusts the G+C content, etc., improves the conformity with Pichia pastoris, and improves the expression efficiency of BoIFN-α and BoIFN-λ.

[0033] 3 The present invention adopts the Pichia pastoris expression system to overcome the problem that the target protein cannot be folded normally and the inclusion body is formed in prokaryotic expression, thereby ensuring the functionality of the target protein.

[0034] 4. The present invention promotes the transcription, translation, and correct folding of BoIFN-α and BoIFN-λ proteins and increases protein expression through a series of genetic modifications. Genes such as PDI, HAC1, and ERO1, which assist in protein folding, are co-expressed with BoIFN-α and BoIFN-λ proteins, and the molecular chaperone PDI is screened out to significantly increase the expression of BoIFN-α and BoIFN-λ proteins; the gene Prb1 encoding serine protease in Pichia pastoris is knocked out using CRISPR technology, which significantly increases the expression of BoIFN-α and BoIFN-λ proteins; the culture conditions of yeast strains are optimized from four factors, namely, induction time, culture medium pH, methanol induction concentration, and culture temperature, to increase the expression of BoIFN-α and BoIFN-λ proteins.

[0035] 5. The product of the present invention can be used to prevent and treat bovine viral diseases, such as foot-and-mouth disease and bovine viral diarrhea. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Schematic diagram of the gene structure of enhancer-BoIFN-α-λ and BoIFN-α-λ in Example 1 of the present invention;

[0037] Figure 2This is a schematic diagram of the PCR identification results of the single enzyme digestion product in Example 2 of the present invention, wherein M is a 2000 bp DNA Marker, 1 is a recombinant plasmid pPIC9K-BoIFN-α-λ, 2 is a linearized recombinant plasmid pPIC9K-BoIFN-α-λ, 3-4 are linearized recombinant plasmids pPIC9K-enhancer-BoIFN-α-λ, and 5 is a recombinant plasmid pPIC9K-enhancer-BoIFN-α-λ;

[0038] Figure 3 Schematic diagram of the PCR results of the bacterial solution in Example 2 of the present invention, wherein Figure AC is the PCR results of the GS115-enhancer-BoIFN-α-λ bacterial solution, the G418 concentration in Figure A is 4.0 mg / mL, M is a 2000 bp DNA Marker, 1 is a positive control, number 2-23 corresponds to strains 4-1 to 4-22, and 24 is a negative control; the G418 concentration in Figure B is 3.0 mg / mL, M is a 2000 bp DNA Marker, 1 is a positive control, number 2-23 corresponds to strains 3-23 to 3-44, and 24 is a negative control; the G418 concentration in Figure C is 2.0 mg / mL, M is a 2000 bp DNA Marker, 1 is a positive control, number 2-23 corresponds to strains 2-45 to 2-66, and 24 is a negative control; Figure DF is the PCR results of the GS115-BoIFN-α-λ bacterial solution, the G418 concentration in Figure D is 1.0 mg / mL, M is a 2000 bp DNA Marker, 1 is the positive control, code 2-23 corresponds to strains 1-1 to 1-22, and 24 is the negative control; the concentration of G418 in Figure E is 2.0 mg / mL, M is a 2000 bp DNA Marker, 1 is the positive control, code 2-23 corresponds to strains 2-23 to 2-44, and 24 is a negative control; the concentration of G418 in Figure F is 3.0 mg / mL and 4.0 mg / mL, M is a 2000 bp DNA Marker, 1 is the positive control, code 2-14 corresponds to strains 3-45 to 3-58, code 15-23 corresponds to strains 4-59 to 4-66, and 24 is a negative control.

[0039] Figure 4Schematic diagram of SDS-PAGE identification results in Example 2 of the present invention, wherein Figure AB is the GS115-enhancer-BoIF N-α-λSDS-PAGE identification results, Figure A G418 concentration is 3.0 mg / mL, M is a protein marker, and coding 1-7 corresponds to strains 3-23, 3-24, 3-26, 3-31, 3-37, 3-41, and 3-42, Figure B G418 concentration is 2.0 mg / mL and 4.0 mg / mL, M is a protein marker, coding 1-4 corresponds to strains 4-1, 4-9, 4-13, and 4-21, coding 5-7 corresponds to strains 2-46, 2-47, and 2-58, Figure CD The results of GS115-BoIFN-α-λSDS-PAGE identification. In Figure C, the concentration of G418 was 3.0 mg / mL, M was a protein marker, and codes 1-6 corresponded to strains 3-46, 3-47, 3-49, 3-52, 3-53, and 3-55. In Figure D, the concentration of G418 was 2.0 mg / mL and 4.0 mg / mL, M was a protein marker, codes 1-3 corresponded to strains 4-59, 4-63, and 4-65, and codes 4-6 corresponded to strains 2-25, 2-34, and 2-43.

[0040] Figure 5 This is a schematic diagram of the western blot identification results of G418 at a concentration of 3.0 mg / mL in Example 2 of the present invention, wherein M is a protein marker, and codes 1-7 correspond to strains 3-23, 3-24, 3-26, 3-31, 3-37, 3-41, and 3-42;

[0041] Figure 6 This is a schematic diagram of the results of single enzyme digestion identification of three molecular chaperone recombinant plasmids in Example 2 of the present invention, wherein M is a 2000 bp DNA Marker, 1 is a linearized pPICZαA-PDI, 2 is pPICZαA-PDI, 3 is a linearized pPICZαA-HAC1, 4 is pPICZαA-HAC1, 5 is a linearized pPICZαA-REO1, and 6 is pPICZαA-REO1;

[0042] Figure 7Schematic diagram of three SDS-PAGE detection results in Example 2 of the present invention, wherein in Figure A, M is a protein marker, 1 is HAC1-5, 2 is HAC1-8, 3 is HAC1-10, 4 is HAC1-12, 5 is HAC1-13, 6 is HAC1-23, 7 is HAC1-25, 8 is HAC1-26, and 9 is HAC1-32; in Figure B, M is a protein marker, 1 is PDI-9, 2 is PDI-17, 3 is PDI-25, 4 is PDI-40, 5 is PDI-41, 6 is PDI-42, 7 is PDI-44, 8 is ERO1-34, 9 is ERO1-35, 10 is ERO1-36, and 11 is ERO1-43;

[0043] Figure 8 This is a schematic diagram of the SDS-PAGE detection results of the Prb1 and Ape3 deletion strains in Example 2 of the present invention, wherein M is a protein marker, 1 is a GS115-enhancer-BoIFN-α-λ strain, 2 is a Prb1 deletion strain, and 3 is an Ape3 deletion strain.

[0044] Fig. 9 This is a schematic diagram of the western blot results of the optimization of fermentation conditions in Example 3 of the present invention, wherein in Figure A, M is a protein Marker, 1-4 are methanol induction concentrations of 0.5%, 1%, 1.5%, and 2%, respectively, and 5-9 are culture medium pH of 4.0, 4.5, 5.0, 5.5, and 6.0, respectively; in Figure B, M is a protein Marker, 1-5 are culture temperatures of 22°C, 24°C, 26°C, 28°C, and 30°C, respectively, and 6-10 are culture times of 24h, 48h, 72h, 96h, and 120h, respectively. DETAILED DESCRIPTION

[0045] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0046] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0047] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0048] Example 1

[0049] This embodiment provides a method for preparing a bovine double interferon gene, comprising the following steps:

[0050] According to the BoIFN-α and BoIFN-λ sequences published in GenBank, primers were designed using Primer premier 5 software to design amplification primers for Bo IFN-α and BoIFN-λ as follows:

[0051] BoIFN-α-F: 5'-ATGGCCCCAGCCTGGTCCTTA-3'

[0052] BoIFN-α-R: 5'-TCAGTCCTTTCTCCTGAAACT-3'

[0053] BoIFN-λ-F: 5'-ATGGCCCCGGGCTGCACGCTG-3'

[0054] BoIFN-λ-R: 5'-TCAGACACACTGGTCTCCGCT-3'.

[0055] After collecting bovine spleen, aseptically separate spleen lymphocytes, stimulate with Con A, extract RNA with RNA extraction kit (Cat. No.: RC311-01, Nanjing Novozyme Biotechnology Co., Ltd.) according to the instructions, reverse transcribe into cDNA, PCR amplify genes BoIFN-α and BoIFN-λ, reverse transcription kit and PCR amplification kit were purchased from Nanjing Novozyme Biotechnology Co., Ltd. (Cat. No.: R212-02, P111). The PCR product was subjected to gel electrophoresis, gel cutting, and the PCR product was recovered with gel DNA extraction kit (Cat. No.: DC301-01, Nanjing Novozyme Biotechnology Co., Ltd.) according to the instructions. The recovered PCR product was sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing, and the sequencing results were as follows:

[0056] BoIFN-α sequence:

[0057] ATGGCCCCAGCCTGGTCCTTACTGCTGGCCCTGCTGCTGCTCAGCTGCAATGCCATCTGCTCTCTGGGCTGCCACCTGCCTCACACCCACAGCCTGGCCAACAGGAGGGTCCTGATGCTCCTGGGACAACTGAGGAGGGTCTCCCCTTCCTCCTGCCTGCAGGACAGAAATGACTTTGCATTCCCCCAGGAGGCGCTGGGTGGCAGCCAGTTGCAGAAGGCTCAAGCCATCTCTGTGCTCCACGAGGTGACCCAGCACACCTTCCAGCTTTTCAGCACAGAGGGCTCGGCCACCATGTGGGATGAGAGCCTCCTGGACAAGCTCCGCGATGCACTGGATCAGCAGCTCACTGACCTGCAATTCTGTCTGAGGCAGGAGGAGGAGCTGCAAGGAGCTCCCCTGCTCAAGGAGGACTCCAGCCTGGCTGTGAGGAAATACTTCCACAGACTCACTCTCTATCTGCAAGAGAAGAGACACAGCCCTTGTGCCTGGGAGGTTGTCAGAGCACAAGTCATGAGAGCCTTCTCTTCCTCAACAAACTTGCAGGAGAGTTTCAGGAGAAAGGACTGA

[0058] Sequence of BoIFN-λ:

[0059] ATGGCCCCGGGCTGCACGCTGGTGCTGGTGCTGATGCTGACGACCGTGGCGCTGAGCAGGACAGGAGCAGTTCCTGTGCCCTCTGCCCCCAGGGCCCTCCCACCTGCCAGGGGCTGCCACGTGGCCCAGTTCAAGTCTCTGTCCCCT CAAGAGCTGCAGGCCTTCAAGACGGCCAGGGATGCCTTTGAAGACTCGTTCTTGCCAAAGGACTGGGACTGCAGCACCCACCTTTTCCCCAGGACCCGGGACCTGAAGCACCTGCAGGTGTGGGAGCGCCCTGTGGCTCTGGAGGCA GAGCTGGCCCTGACACTGACGGTCCTGGAGGCCATGGCTAACTCATCCCTGGGCCACAGCCTGGAGCAGCCCCTTCTCACGCTGCAGAACATCCACTCCAAGCTCCAGGCCTGTGTCCCAGCTCAGCCCACAGCAAGCTCCAGGCCC CGGGGCCGCCTCCACCACTGGCTGCACCGCCTCCAGGAGGCCCGGAAGGAGTCCCAGGACTGCCTCGAAGCCTCTGTGATGTTCAACCTCCTCCGCCTCCTCACCCGGGACCTGAAATGTGTTGCCAGCGGAGACCAGTGTGTCTGA

[0060] According to the BoIFN-α and BoIFN-λ gene sequences, two sequences were designed and synthesized. First, the BoIFN-α and BoIFN-λ gene sequences were analyzed using the SignalP online database. After removing the signal peptide sequences of the two interferons, BoIFN-α and BoIFN-λ (referred to as BoIFN-α-λ) were connected using a flexible linker. The Pichia signal peptide α-mating factor (α-factor) of the first sequence was connected to the enhancer through the self-cleaving 2A peptide (P2A), and the enhancer was connected to BoIFN-α-λ through P2A. This sequence was named enhancer-BoIFN-α-λ (see Figure 1 A). The α-factor of the second sequence is connected to BoIFN-α-λ through P2A, and this sequence is named BoIFN-α-λ (see Figure 1B). According to the codon preference of the Pichia pastoris expression system, the codon adaptation index and GC content of all sequences were optimized under the premise that the amino acid sequence remained unchanged; the rare codons in the gene were replaced with the dominant codons of Pichia pastoris; the AT-rich region was eliminated to prevent the premature termination of the transcription reaction, and the G+C content was adjusted to ensure that the G+C content of the optimized target gene was basically consistent with that of Pichia pastoris, and the gene conformity was improved. The gene sequence after the enhancer-BoIFN-α-λ sequence optimization was the bovine double interferon gene, and its nucleotide sequence is shown in SE Q ID NO.1.

[0061] Example 2

[0062] This embodiment provides a method for preparing a recombinant Pichia pastoris engineering bacterium expressing the bovine double interferon gene of Example 1, comprising the following steps:

[0063] (1) The bovine interferon-enhancer and optimized BoIFN-α-λ sequences were connected to the pPIC9K vector and named pPIC9K-enhancer-BoIFN-α-λ and pPIC9K-BoIFN-α-λ, respectively.

[0064] (2) The recombinant plasmids pPIC9K-enhancer-BoIFN-α-λ, pPIC9K-BoIFN-α-λ and the empty vector pPIC9K were digested with SacⅠ. The reaction system is shown in Table 1. The digestion products were identified by PCR. The results of agarose gel electrophoresis showed that the vector had been linearized (see Figure 2 ). Then use a DNA product purification kit to recover the linearized plasmid.

[0065] Table 1 Enzyme digestion system

[0066] Reagents Dosage 10×NEBBuffer 5μL(1×) DNA 1 μg SacⅠRestriction Enzyme 1μL(10units) Nuclease-freeWater To50μL

[0067] Prepare competent cells GS115 according to the instructions of the Pichia pastoris competent preparation kit (Cat. No.: SK2430, Beijing Coolbo Technology Co., Ltd.), transform the linearized recombinant plasmid and empty plasmid into competent cells GS115 respectively, add the plasmid to the unmelted competent cells, place in a 30°C water bath, and mix by inversion every 15s until the competent cells are completely melted. Add 1.4mL B2 solution and mix by inversion, place in a water bath at 30°C for 60min, then centrifuge at 3000rpm for 3min, discard the supernatant and keep the bacterial pellet, add 1mL B3 solution to resuspend the bacterial cells. After centrifugation at 3000rpm for 3min, discard the supernatant and keep the bacterial pellet, add 100μL B3 solution to resuspend the bacterial cells, and spread all 100μL of the bacterial cells on the MD plate medium, and culture at 30°C for 3-5 days until yeast colonies appear on the plate. Pick a single colony on the MD plate, inoculate it point-to-point on the MM plate culture medium, and culture it at 30℃ for 2-3 days. After the colonies grow, rinse the MM plate with YPD culture medium, and apply YPD plate culture medium containing 1.0, 2.0, 3.0, and 4.0 mg / mL G418 respectively. Culture at 30℃ for 2-3 days until yeast colonies appear. Pick 50-100 single colonies on each YPD plate culture medium containing G418, place them in 2mL YPD liquid culture medium and culture them for 14-16 hours. Take a small amount of bacterial solution from all strains, freeze it in a -80℃ refrigerator, then boil it to melt. Use the vector universal primers 5'AOX1-F and 3'AOX1-R as a template to perform bacterial solution PCR identification on all strains (Cat. No.: CW0690H, Jiangsu Kangwei Century Biotechnology Co., Ltd.), and for agarose gel electrophoresis, refer to Figure 3 The results showed that the target band of the correct size was obtained after PCR, indicating that the enhancer-BoIFN-α-λ gene and BoIFN-α-λ gene were successfully integrated into the yeast genome. The recombinant yeast were named GS115-enhancer-BoIFN-α-λ and GS115-BoIFN-α-λ.

[0068] To screen highly efficient expression strains, according to the above PCR results, 20 positive strains were selected from the positive results of GS115-enhancer-BoIFN-α-λ and GS115-BoIF N-α-λ, and each concentration of G418 was induced to express in a micro-amount. The culture was inoculated into YPD medium at 1% inoculum, cultured at 30°C and stirring speed of 250r / min for 16-18h, and then the YPD culture was inoculated into BMGY medium at 10% inoculum, cultured at 30°C and stirring speed of 250r / min until OD 600 When the OD reaches 2.0-6.0, the bacterial solution is centrifuged and the cell pellet is resuspended in BMMY medium to an OD of 600The concentration of 1 mL of the induced supernatant was 1.0, and the expression level of the recombinant fusion protein was detected by SDS-PAGE after TCA concentration.

[0069] The results showed that the GS115-enhancer-BoIFN-α-λ yeast containing the enhancer expressed the target protein 80% higher than the GS115-BoIFN-α-λ yeast. Moreover, the recombinant yeast with a concentration of 3.0 of GS115-enhancer-BoIFN-α-λ expressed the target protein 120% and 60% higher than that with a concentration of 2.0 and 4.0 (see Figure 4 ). We further selected the recombinant yeast with a concentration of 3.0 for western blot verification, and the results showed that strain 3-31 expressed the highest recombinant protein content (see Figure 5 ), therefore, recombinant yeast No. 3-31 was selected as the engineering bacteria for producing recombinant bovine interferon BoIFN-α and Bo IFN-λ, and was recorded as GS115-enhancer-BoIFN-α-λ.

[0070] (3) The molecular chaperones PDI (AJ302014.1), HAC1 (XM_002489994), and ERO1 (XM_002490982.1) that assist in protein folding were selected, and their gene sequences were codon optimized. They were then artificially synthesized by Suzhou Hongxun Biotechnology Co., Ltd. and cloned into the pPICZαA vector and named pPICZαA-PDI, pPICZαA-HAC1, and pPICZαA-ERO1, respectively.

[0071] (4) The pPICZαA-PDI, pPICZαA-HAC1, and pPICZαA-ERO1 plasmids were digested with SacI restriction enzyme, and the digestion products were identified by PCR. The agarose gel electrophoresis results showed that the vectors had been linearized (see Figure 6). The linearized pPICZαA-PDI, pPICZαA-HAC1, and pPICZαA-ERO1 plasmids were transformed into competent cells GS115-enhancer-BoIFN-α-λ, respectively. The transformation method is as shown in step (2). The transformed bacterial solution was spread on a bleomycin-resistant (100 μg / mL) YPD plate medium and cultured at 30°C for 2-3 days. The positive colonies were picked and added to 2 mL of YPD medium. The culture was cultured at 30°C and 250 rpm for 16-18 hours. A small amount of bacterial solution was taken for PCR identification. The positive strains identified by PCR were screened for micro-induction expression. The induction expression method is as shown in step (2). The expression supernatant was taken for SDS-PAGE detection. The results showed that the synchronous expression of molecular chaperones can increase the expression levels of recombinant bovine interferons BoIFN-α and BoIFN-λ, and the molecular chaperone PDI has the most obvious effect (see Figure 7 ), selected the PDI-42 strain and named it the GS115-enhancer-BoIFN-α-λ-PDI recombinant strain;

[0072] (5) Search for sgRNA for knocking out the target gene on https: / / zlab.bio / guide-design-resources, select 20bp as the target site for knocking out the gene, design plasmids and primers using SnapGene software, and linearize the plasmid backbone using pPpT4 as a template for reverse PCR. Perform agarose electrophoresis on the PCR product, recover the gel and take 100ng for chemical transformation into E.coli JM109 to connect into a ring. After successful verification, use a plasmid mini-extraction kit to extract the plasmid for use. Fungal DNA Mini Kit (OMEGA) was used to extract Pichia pastoris genomic DNA. Knockout plasmids were constructed based on the sgRNA of the target gene, and homologous segments of about 1000 bp upstream and downstream of the target gene were selected for amplification. The upstream and downstream homologous arms were connected by fusion PCR to construct knockout overlapping arms. Thaw the EP tube containing 40 μL of GS115-enhancer-BoIFN-α-λ-PDI recombinant strain on ice, add 100 ng of knockout plasmid and 500 ng of homology arm fragment, mix by pipetting, and transfer to a pre-cooled electroporation cup. After electroporation, immediately add pre-cooled 0.5 mL of YPD medium and 0.5 mL of 1 M D-sorbitol, mix by pipetting, and transfer to a new 1.5 mL EP tube. After resuscitation at 30°C, 200 r / min for 2 hours, spread on an ampicillin-resistant plate, and screen positive transformants to obtain the Prb1 deletion strain GS115-enhancer-BoIFN-α-λ-PD I-ΔPrb1 and the Ape3 deletion strain GS115-enhancer-BoIFN-α-λ-PDI-ΔApe3. The results of SDS-PAGE detection showed that both GS115-enhancer-BoIFN-α-λ-PDI-ΔPrb1 and GS115-enhancer-BoIFN-α-λ-PDI-ΔApe3 could reduce the degradation of recombinant proteins and increase the expression levels of BoIFN-α and BoIFN-λ proteins, but the protein expression level of GS115-enhancer-BoIFN-α-λ-PDI-ΔPrb1 was 80% higher than that of GS 115-enhancer-BoIFN-α-λ-PDI-ΔApe3 (see Figure 8 GS115-enhancer-BoI FN-α-λ-PDI-ΔPrb1 was biologically deposited with the deposit number: CCTCC NO: M20241194.

[0073] Example 3

[0074] This example provides a recombinant Pichia pastoris antiviral activity assay.

[0075] (1) The culture conditions of the GS115-enhancer-BoIFN-α-λ-PDI-ΔPrb1 strain were optimized from four factors: induction time, medium pH, methanol induction concentration, and culture temperature. For this purpose, a single factor experiment was conducted. The preserved strain was revived in YPD culture medium and inoculated into BMGY medium and cultured at 30°C and 250 r / min for 18 h. When the OD 600When it reaches about 40, 2% is transferred to BMMY medium for induction. The pH of the induction medium BMMY is 4.0, 4.5, 5.0, 5.5, and 6.0, respectively. The induction temperatures are 22°C, 24°C, 26°C, 28°C, and 30°C, respectively. The maintenance concentrations of methanol are 0.5%, 1%, 1.5%, and 2%, respectively. 24h, 48h, 72h, 96h, and 120h after induced expression, the expression supernatant is taken for western blot detection of the expression level of the recombinant fusion protein. The results showed that the optimal fermentation conditions for recombinant bovine interferon BoIFN-α and BoIFN-λ are: culture temperature 28°C, methanol induction concentration 0.5%, culture medium pH 6.0, and culture time 120h (see Fig. 9 ).

[0076] (2) The yeast strain GS115-enhancer-BoIFN-α-λ-PDI-ΔPrb1 was fermented to express BoIFN-α and BoIFN-λ proteins. The fermentation conditions and fermentation operations were performed according to step S1. After the fermentation was completed, 50 ml of the supernatant was added to an ultrafiltration tube with a molecular weight cutoff of 10 kDa, centrifuged at 4 ° C and a rate of 5000 rpm, and the upper protein concentrate was collected, about 6 ml. The concentrated sample was then added to a 100 kDa ultrafiltration tube, centrifuged at 4 ° C and a rate of 5000 rpm, and the filtrate below was collected, about 5 ml, and the sample was finally purified and concentrated 10 times.

[0077] The anti-VSV-GFP titer of recombinant BoIFN-α-λ was determined by cytopathic inhibition assay. Bovine kidney cells (MDBK) were inoculated into 96-well plates. After the cells adhered to the wall, the 10% fetal bovine serum DMEM medium was discarded and 100 μL of the induction stock solution BoIFN-α-λ (4 -1 to 4 -11 dilution) or purified BoIFN-α-λ (4 -1 to 4 -11 Each dilution was diluted in multiple ratios, and 5 wells were set as controls for each dilution. After incubation at 37°C for 24 hours, 100 TCID / 0.1 mL of VSV-GFP was added to each well. The fluorescence intensity was observed after 24 hours. A blank control group and a virus control group were set up at the same time. When the negative wells had no lesions and the lesion rate of the positive wells was not less than 80%, the wells with interferon added and the cell protection rate was not less than 50% were marked as effective protection wells, and the protection titer was calculated by the Reed-Muench method. The results showed that the anti-VSV activity of the original solution BoIFN-α-λ and the purified BoIFN-α-λ were 1.16×10 6 U / mL and 4.3×10 7 U / mL.

[0078] Although the principles of the present invention are described in detail above in conjunction with the preferred embodiments of the present invention, those skilled in the art should understand that the above embodiments are merely explanations of the exemplary implementations of the present invention, and are not intended to limit the scope of the present invention. The details in the embodiments do not constitute limitations on the scope of the present invention, and any obvious changes such as equivalent transformations, simple replacements, etc. based on the technical solution of the present invention, without departing from the spirit and scope of the present invention, fall within the protection scope of the present invention.

Claims

1. A bovine double interferon gene, characterized in that: The nucleotide sequence of the bovine dual interferon gene is shown in SEQ ID NO.

1.

2. A method for preparing the bovine double interferon gene according to claim 1, characterized in that: The following steps are involved: S1: RNA was extracted from bovine spleen lymphocytes stimulated with Concanavalin A and reverse transcribed, and PCR amplification was performed using amplification primers using RNA as a template to recover and sequence the bovine interferon α and bovine interferon λ genes to obtain BoIFN-α and BoIFN-λ sequences; S2: After removing the signal peptide sequence from the BoIFN-α and BoIFN-λ sequences, the two gene sequences are connected using a flexible linker to obtain a BoIFN-α-λ sequence; S3: After the Pichia pastoris signal peptide α-mating factor is connected to the N-terminus of the enhancer through the self-cleaving 2A peptide, the C-terminus of the enhancer is connected to the BoIFN-α-λ sequence through the self-cleaving 2A peptide to obtain the enhancer-BoIFN-α-λ sequence; S4: After replacing rare codons in the enhancer-BoIFN-α-λ sequence with Pichia pastoris dominant codons, eliminating AT-rich regions, and adjusting the G+C content in the sequence to be consistent with the G+C content in Pichia pastoris, the bovine bi-interferon gene is obtained.

3. A recombinant expression vector containing the bovine double interferon gene according to claim 1. A host cell containing the recombinant expression vector according to claim 3.

5. A recombinant Pichia pastoris engineered bacterium, characterized in that: Express the bovine double interferon gene according to claim 1.

6. The recombinant Pichia pastoris engineered bacterium according to claim 5, characterized in that: The biological preservation number of the recombinant Pichia pastoris engineering bacteria is: CCTCC NO: M20241194.

7. A method for preparing the recombinant Pichia pastoris engineered bacteria according to claim 5 or 6, characterized in that: The following steps are involved: (1) connecting the bovine interferon gene described in claim 1 to the pPIC9K vector to obtain the pPIC9K-enhancer-BoIFN-α-λ recombinant vector; (2) After linearizing the pPIC9K-enhancer-BoIFN-α-λ recombinant vector, transforming it into competent cells GS115, culturing it, identifying, inducing and screening it, and obtaining a GS115-enhancer-BoIFN-α-λ recombinant strain; (3) After codon optimization, the molecular chaperone PDI was cloned into the pPICZαA vector to obtain the pPICZαA-PDI recombinant vector; (4) After linearization, the PICZαA-PDI recombinant vector was transformed into the competent cell GS115-enhancer-BoIFN-α-λ and cultured to obtain the GS115-enhancer-BoIFN-α-λ-PDI recombinant strain; (5) After knocking out the Prb1 gene in the GS115-enhancer-BoIFN-α-λ-PDI recombinant strain, identification, induction and screening are performed to obtain the recombinant Pichia pastoris engineered strain.

8. The method for preparing the recombinant Pichia pastoris engineering bacteria according to claim 7, characterized in that: In step (2) and step (5), the induction method is: The identified strains were inoculated into YPD medium at 1% inoculation volume, and cultured at 30°C and 250 r / min for 16-18 h. Then, the YPD culture was inoculated into BMGY medium at 10% inoculation volume, and cultured at 30°C and 250 r / min until OD 600 When the OD reaches 2.0-6.0, the bacterial solution is centrifuged and the cell pellet is resuspended in BMMY medium to an OD of 600 was 1.0, and finally induced culture was carried out at 28°C and a stirring speed of 250 r / min. 100% methanol was added every 24 hours to a final concentration of 0.5%, and culture was continued for 96 hours.

9. Use of the recombinant Pichia pastoris engineered bacterium according to claim 5 or 6 in combating bovine viral diseases.

10. The use according to claim 9, wherein the bovine viral diseases include foot-and-mouth disease and bovine viral diarrhea.

Citation Information

Patent Citations

  • Large-scale combined car transduction and crispr gene editing of b cells

    CA3162900A1

  • Animal genetic engineering interferon alpha and gamma composite preparations and production method and clinical application thereof

    CN101209345A

  • Preparation method of heterologous bluetongue virus double-strand RNA (ribonucleic acid) endogenous interferon inducer

    CN102350001A

  • Recombined bovine alpha interferon and application thereof

    CN103450355A

  • Recombinant protein, nucleic acid encoding recombinant protein, and application of recombinant protein and nucleic acid

    CN111087461A